Generic Name and Formulations:
Neostigmine methylsulfate 0.5mg/mL, 1mg/mL; soln for IV inj; latex-free.
Indications for BLOXIVERZ:
To reverse effects of non-depolarizing neuromuscular blocking agents (NMBAs) post-op.
Adults and Children:
See full labeling. Peripheral nerve stimulator and monitoring for twitch responses should be used to determine time of Bloxiverz initiation and the need for additional doses. Individualize. Give by IV inj slowly over a period of at least 1 min. Administer an anticholinergic (eg, atropine sulfate, glycopyrrolate) prior to (if bradycardia present) or concomitantly with Bloxiverz. Reversal of NMBAs with shorter half-lives (eg, rocuronium), or when first twitch response is substantially >10% of baseline or when a second twitch is present: 0.03mg/kg. Reversal of NMBAs with longer half-lives (eg, vecuronium, pancuronium) or when first twitch response is not substantially >10% of baseline or if rapid recovery required: 0.07mg/kg. Max total dose: 0.07mg/kg or up to a total of 5mg, whichever is less.
Peritonitis. Mechanical obstruction of the intestinal or urinary tract.
Should be administered by trained healthcare providers. Have treatment for anaphylaxis readily available. Maintain ventilation and patent airway. Increased risk of BP and HR complications with cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome) or myasthenia gravis. Neuromuscular dysfunction with large doses; reduce dose if recovery is nearly complete. Differentiate between myasthenic or cholinergic crisis. Renal or hepatic impairment; monitor closely. Elderly (monitor for longer periods). Labor & delivery: may induce premature labor. Pregnancy. Nursing mothers.
Caution with other drugs that may alter activity of metabolizing enzymes or transporters.
Bradycardia, nausea, vomiting, dry mouth, hypotension, dizziness, headache, insomnia, dyspnea, pruritus; hypersensitivity reactions.
Multi-dose vials (10mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma